Oncology Corporate Profile
Trovagene is a precision medicine biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary Precision Cancer Monitoring® (PCM) technology in tumor genomics. Trovagene has broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies. Trovagene offers its PCM technology at its CLIA/CAP – accredited laboratory and plans to continue to vertically integrate its PCM technology with precision cancer therapeutics.
|Brand / Product||Class||Area of Study||Phase||Partnership|
|PCM-075||PLK1 inhibitor||Acute Myelogenous Leukemia (AML)||I|
|PCM-075 (+ decitabine)||PLK1 inhibitor||Acute Myelogenous Leukemia (AML)||I|
|PCM-075||PLK1 inhibitor||Various cancer types||I|
View additional information on product candidates here »